Key terms
About TSHA
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TSHA news
Apr 22
3:37pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Apr 09
5:05am ET
Buy Rating on Taysha Gene Therapies with TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue Growth
Apr 05
8:01am ET
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
Mar 28
8:16am ET
Taysha Gene Therapies (TSHA) Gets a Buy from Truist Financial
Mar 21
7:35am ET
Positive Clinical Trials Bolster Buy Rating for Taysha Gene Therapies
Mar 21
6:40am ET
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Viridian Therapeutics (VRDN)
Mar 21
4:57am ET
Taysha Gene Therapies price target raised to $7 from $5 at Chardan
Mar 21
2:38am ET
Buy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study Catalysts
Mar 21
2:00am ET
Taysha Gene Therapies On Edge: The High Stakes of TSHA-102’s Regulatory Approval Journey
Mar 20
10:25pm ET
Buy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial Health
Mar 20
8:57am ET
Taysha Gene Therapies price target raised to $7 from $5 at Needham
Mar 20
8:01am ET
Taysha Gene Therapies up 29% in pre-market at $2.91 following FY23 results
Mar 20
8:01am ET
Taysha Gene Therapies reports Q4 EPS (96c), consensus ($1.47)
Mar 20
6:55am ET
Buy Rating Reaffirmed for Taysha Gene Therapies Amid Clinical Progress and Financial Stability
Mar 20
12:40am ET
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Taysha Gene Therapies (TSHA)
Mar 19
8:06am ET
Options Volatility and Implied Earnings Moves Today, March 19, 2024
Mar 18
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 18 – March 21, 2024
Mar 01
7:56am ET
Buy Rating Affirmed: Taysha Gene Therapies’ Accelerated Clinical Progress and Upcoming Data Releases
Mar 01
4:59am ET
Buy Rating Affirmed for Taysha Gene Therapies Amid Positive Rett Syndrome Program Developments
Feb 29
12:05pm ET
Buy Rating and Increased Price Target for Taysha Gene Therapies Amidst Promising Clinical Trial Advancements
Feb 29
9:45am ET
Buy Rating Affirmed for Taysha Gene Therapies Amid Positive REVEAL Study Advancements and Strategic Intrathecal Administration Approach
Feb 29
8:21am ET
Taysha Gene Therapies announces updates to TSHA-102 program
Feb 21
8:13am ET
Buy Rating Affirmed for Taysha Gene Therapies Amid Promising TSHA-102 Trials and Market Potential
Feb 15
4:36pm ET
Taysha Gene Therapies provides update on deprioritized pipeline programs
Feb 02
8:02am ET
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
No recent press releases are available for TSHA
TSHA Financials
Key terms
Ad Feedback
TSHA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TSHA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
